Anne Dillon, MD
Family Medicine · Cincinnati, OHNPI 1174624159
Payments from drug & device makers
Across 558 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Novo Nordisk$2K
- AstraZeneca$1K
- Lilly USA, LLC$860
- Amgen$637
- Pfizer$543
- plus $3K from 32 others
What the payments were for
- Speaking & faculty fees$2,40022%
- Food & beverage$8,75378%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 42 | $3,091 |
| Novo Nordisk | 88 | $1,547 |
| AstraZeneca | 31 | $1,046 |
| Lilly USA, LLC | 80 | $860 |
| Amgen | 43 | $637 |
| Pfizer | 42 | $543 |
| GSK | 42 | $462 |
| Merck | 32 | $431 |
| Boehringer Ingelheim | 23 | $359 |
| Johnson & Johnson | 18 | $271 |
| Exact Sciences | 12 | $225 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $202 |
| Abbott | 12 | $202 |
| Amarin Pharma, Inc. | 10 | $187 |
| Sanofi-aventis U.S. LLC | 8 | $139 |
| Axsome Therapeutics, Inc. | 5 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $122 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $96 |
| Novartis | 6 | $93 |
| Bayer | 4 | $75 |
| Kowa Pharmaceuticals America, Inc. | 5 | $72 |
| Dexcom, Inc. | 4 | $71 |
| Medtronic(2 entities) | 2 | $49 |
| Otsuka America Pharmaceutical, Inc. | 3 | $48 |
| Phadia US Inc. | 2 | $28 |
| Eisai Inc. | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Dynavax Technologies Corporation | 2 | $18 |
| Genentech USA, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
| Shire North American Group Inc | 1 | $12 |
| Mannkind Corporation | 1 | $12 |
| Hikma Pharmaceuticals USA | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Dermira, Inc. | 1 | $11 |
| Sumitomo Pharma America, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,161 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 69 | $64,808 |
| JardianceEmpagliflozin | 69 | $62,363 |
| RybelsusSemaglutide | 40 | $43,915 |
| OzempicSemaglutide | 37 | $41,505 |
| TrulicityDulaglutide | 18 | $26,782 |
| EliquisApixaban | 22 | $26,675 |
| XareltoRivaroxaban | 18 | $18,596 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $9,166 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $7,364 |
| Atorvastatin Calcium | 625 | $5,561 |
| BrilintaTicagrelor | 26 | $5,064 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,747 |
| VascepaIcosapent Ethyl | 12 | $3,981 |
| LantusInsulin Glargine,hum.Rec.Anlog | 11 | $2,159 |
| SynthroidLevothyroxine Sodium | 33 | $2,139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $1,547 | $85,42077 claims |
| AstraZenecaFarxiga, Brilinta | $1,046 | $69,87295 claims |
| Boehringer IngelheimJardiance | $359 | $62,36369 claims |
| Lilly USA, LLCTrulicity | $860 | $26,78218 claims |
| PfizerEliquis | $543 | $26,67522 claims |
| Johnson & JohnsonXarelto | $271 | $18,59618 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $462 | $13,91226 claims |
| Sanofi-aventis U.S. LLCLantus | $139 | $2,15911 claims |
| AbbVieSynthroid | $3,091 | $2,13933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Cincinnati
- Michael ButcherCincinnati$18.3M
- Paul NugentCincinnati$4.9M
- Rajesh DavitCincinnati$2M
- Michael HeileCincinnati$272K
- Michael NossCincinnati$265K
- Amy MechleyCincinnati$120K
- Melissa SchroerCincinnati$116K
- William CoxCincinnati$52K
- Frank PerrinoCincinnati$49K
- Sean LyndCincinnati$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.